A Pilot, Phase I/II Study of the Amino Acid Leucine in the Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia

Status: Recruiting
DFCI Protocol ID:

This study will determine the safety and possibility of giving the amino acid, leucine, in patients with Diamond Blackfan anemia(DBA)who are on dependent on red blood cell transfusions. The leucine is expected to produce a response in patients with DBA to the point where red blood cell production is increased. Red cell transfusions can then be less frequent or possibly discontinued. The investigators will study the side effects, if any, of giving leucine to DBA patients. Leucine levels of leucine will be obtained at baseline and during the study. The drug leucine will be provided in capsule form and taken 3 times a day for a total of 9 months.

Conducting Institutions:

Children's Hospital Boston, Dana-Farber Cancer Institute

Overall PI:

Colin Sieff, MD, Children's Hospital Boston

Site-responsible Investigators:


Dana-Farber Cancer Institute: Childrens Hospital Pediatric Clinical Translation Investigation Program CTIP, ctip@partners.org

Eligibility Criteria

Inclusion Criteria:

  -  diagnosed with Diamond Blackfan anemia as published in British Journal of Hematology

  -  transfusion dependent

  -  age 2 years and older

  -  adequate renal function

  -  adequate liver function

  -  negative B-HCG if patient is a menstruating female and documentation of adequate

  -  signed informed consent

Exclusion Criteria:

  -  Known hypersensitivity to branched chain amino acids

  -  Diagnosis of an inborn error of amino acid metabolism disorder

  -  Prior hematopoietic stem cell transplantation

  -  Pregnancy, or plans to become pregnant during duration of trial

Know Your Options

Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.
We can help you navigate your options.

Get Clinical Trial Updates


Stay informed about Dana-Farber/Boston Children's research efforts, including information on new and current clinical trials. Sign up to receive our email newsletter Advances in Pediatric Hematology/Oncology.